These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 6199450)
1. The electrophysiologic effects of oral cibenzoline. Kushner M; Magiros E; Peters R; Carliner N; Plotnick G; Fisher M J Electrocardiol; 1984 Jan; 17(1):15-23. PubMed ID: 6199450 [TBL] [Abstract][Full Text] [Related]
2. Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration. Touboul P; Atallah G; Kirkorian G; de Zuloaga C; Dufour A; Aymard MF; Lavaud P; Moleur P Am Heart J; 1986 Aug; 112(2):333-9. PubMed ID: 3526853 [TBL] [Abstract][Full Text] [Related]
3. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia. Hoffmann E; Mattke S; Haberl R; Steinbeck G J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686 [TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias. Browne KF; Prystowsky EN; Zipes DP; Chilson DA; Heger JJ J Am Coll Cardiol; 1984 Mar; 3(3):857-64. PubMed ID: 6693656 [TBL] [Abstract][Full Text] [Related]
5. [Electrophysiologic properties of cibenzoline in Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia]. Kühlkamp V; Ickrath O; Schmid F; Mayer F; Haasis R; Seipel L Z Kardiol; 1989 Oct; 78(10):640-6. PubMed ID: 2686251 [TBL] [Abstract][Full Text] [Related]
6. Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia. Rothbart ST; Saksena S Am J Cardiol; 1986 Apr; 57(11):941-6. PubMed ID: 3515898 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic effects and efficacy of cibenzoline on stimulation-induced atrial fibrillation and flutter and implications for treatment of paroxysmal atrial fibrillation. Kühlkamp V; Meerhof J; Schmidt F; Mayer F; Ickrath O; Haasis R; Seipel L Am J Cardiol; 1990 Mar; 65(9):628-32. PubMed ID: 2309633 [TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic use of cibenzoline, a new class 1 antiarrhythmic agent with class 3 and 4 properties, in patients with recurrent ventricular tachycardia. Cocco G; Strozzi C; Pansini R; Rochat N; Bulgarelli R; Padula A; Sfrisi C; Kamal Al Yassini A Eur Heart J; 1984 Feb; 5(2):108-14. PubMed ID: 6723683 [TBL] [Abstract][Full Text] [Related]
10. [Electrophysiologic study of cibenzoline in patients with paroxysmal atrial fibrillation with special reference to atrial fibrillation threshold]. Inoue D; Ishibashi K; Sakai R; Inoue M; Omori I; Asayama J; Nakagawa M Kokyu To Junkan; 1992 Dec; 40(12):1203-8. PubMed ID: 1480832 [TBL] [Abstract][Full Text] [Related]
11. [Cibenzoline: electrophysiologic effects of a new class I anti-arrhythmia agents in supraventricular tachycardia]. Pfitzner P; Manz M; Schütz R; Lüderitz B Z Kardiol; 1989 Oct; 78(10):654-60. PubMed ID: 2686252 [TBL] [Abstract][Full Text] [Related]
12. [Anti-arrhythmia and pro-arrhythmia effects of oral cibenzoline therapy in sustained ventricular tachycardia]. Hoffmann E; Bach P; Haberl R; Mattke S; Steinbeck G Z Kardiol; 1992 Jul; 81(7):378-84. PubMed ID: 1509795 [TBL] [Abstract][Full Text] [Related]
13. [Effect of a new class I anti-arrhythmia agent cibenzoline in patients with therapy refractory, sustained ventricular tachycardias]. Kühlkamp V; Ickrath O; Haasis R; Seipel L Z Kardiol; 1988 Sep; 77(9):595-9. PubMed ID: 3195178 [TBL] [Abstract][Full Text] [Related]
14. [Injectable and oral cibenzoline in the treatment of supraventricular tachycardia related to intranodal reentry or accessory atrioventricular conduction pathway]. Fauchier JP; Rouesnel P; Breuillac JC; Cosnay P; Scheck F; Garnier LF Ann Cardiol Angeiol (Paris); 1994 Apr; 43(4):194-203. PubMed ID: 8024234 [TBL] [Abstract][Full Text] [Related]
15. Effects of intravenous cibenzoline on ventricular vulnerability and electrophysiology in patients with sustained ventricular tachycardia in comparison to a control group. Kühlkamp V; Schmid F; Mayer F; Ickrath O; Haasis R; Seipel L J Cardiovasc Pharmacol; 1990 Mar; 15(3):472-5. PubMed ID: 1691372 [TBL] [Abstract][Full Text] [Related]
16. Crossover comparison of cibenzoline and quinidine in ambulatory patients with chronic ventricular arrhythmias. Mohiuddin SM; Woodruff MP; Esterbrooks DJ; Mooss AN; Hansen JM; Hilleman DE J Cardiovasc Pharmacol; 1989 Apr; 13(4):525-9. PubMed ID: 2470988 [TBL] [Abstract][Full Text] [Related]
17. Cibenzoline for treatment of ventricular arrhythmias: a double-blind placebo-controlled study. Kostis JB; Krieger S; Moreyra A; Cosgrove N J Am Coll Cardiol; 1984 Aug; 4(2):372-7. PubMed ID: 6376595 [TBL] [Abstract][Full Text] [Related]
19. Electrophysiologic effects and efficacy of cibenzoline in patients with supraventricular tachycardia. Fujiki A; Mizumaki K; Tani M; Yoshida S; Sasayama S J Cardiovasc Pharmacol; 1992 Sep; 20(3):375-9. PubMed ID: 1279281 [TBL] [Abstract][Full Text] [Related]
20. Cibenzoline for symptomatic ventricular arrhythmias: a prospective, randomized, double-blind, placebo controlled trial and a long term open label study. Lee MA; Fenster PE; Garcia ZM; Kipps JE; Huang SK Can J Cardiol; 1989 Sep; 5(6):295-8. PubMed ID: 2477130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]